1. R.J. Hagerman, E. Berry-Kravis, H.C. Hazlett, D.B. Bailey, H. Moine, R.F. Kooy, et al. Fragile X syndrome, Nat. Rev. Dis. Primers. 3 (1) (2017) 1-19,

2. K.G. Monaghan, E. Lyon, E.B. Spector. ACMG Standards and Guidelines for fragile X testing: a revision to the disease-specific supplements to the Standards and Guidelines for Clinical Genetics Laboratories of the American College of Medical Genetics and Genomics, Genet Med .15 (7) (2013) 575-586, https://doi.org/ 10.1038/gim.2013.61 [DOI:10.1038/gim.2013.61]

3. Salcedo-Arellano MJ, Dufour B, McLennan Y, Martinez-Cerdeno V, Hagerman R. Fragile X syndrome and associated disorders: clinical aspects and pathology. Neurobiol. Dis. 2020 Mar 1;136:104740.

4. J. Hunter, O. Rivero‐Arias, A. Angelov, E. Kim, I. Fotheringham, J. Leal. Epidemiology of fragile X syndrome: A systematic review and meta‐analysis, Am. J. Med. Genet. Part A.164 (7) (2014) 1648-1658, https://doi.org/ 10.1002/ajmg.a.36511 [DOI:10.1002/ajmg.a.36511]

5. Hagerman RJ, Protic D, Rajaratnam A, Salcedo-Arellano MJ, Aydin EY, Schneider A. Fragile X-associated neuropsychiatric disorders (FXAND). Front Psychiatry. 2018:564.

6. J. Rohr, E. Allen, K. Charen, J. Giles, W. He, C. Dominguez, et al. Anti-Mullerian hormone indicates early ovarian decline in fragile X intellectual disability (FMR1) premutation carriers: a preliminary study, Hum Reprod. 23 (5) (2008) 1220-1225,

7. A. Sullivan, M. Marcus, M. Epstein, E. Allen, A. Anido, J. Paquin, et al. Association of FMR1 repeat size with ovarian dysfunction, Hum Reprod. 20 (2) (2005) 402-412, https://doi.org/ 10.1093/humrep/deh635 [DOI:10.1093/humrep/deh635]

8. D. Heine‐Suñer, L. Torres‐Juan, M. Morla, X. Busquets, F. Barcelo, G. Pico, et al. Fragile‐X syndrome and skewed X‐chromosome inactivation within a family: A female member with complete inactivation of the functional X chromosome, Am. J. Med. Genet. Part A.122 (2) (2003) 108-114. , https://doi.org/ 10.1002/ajmg.a.20160 [DOI:10.1002/ajmg.a.20160]

9. F.A. Nahhas, T.J. Monroe, T.W. Prior, P.I. Botma, J. Fang, P.J. Snyder, et al. Evaluation of the human fragile X intellectual disability 1 polymerase chain reaction reagents to amplify the FMR1 gene: testing in a clinical diagnostic laboratory, GENET TEST MOL BIOMA.16 (3) (2012) 187-192, https://doi.org/ 10.1089/gtmb.2011.0128 [DOI:10.1089/gtmb.2011.0128]

10. E. Tabolacci, M.G. Pomponi, L. Remondini, R. Pietrobono, V. Nobile, G. Pennacchio, et al. Methylated premutation of the FMR1 gene in three sisters: correlating CGG expansion and epigenetic inactivation, Eur J Med Genet .28 (5) (2020) 567-575, https://doi.org/ 10.1038/s41431-019-0554-7 [DOI:10.1038/s41431-019-0554-7]

11. L. Martorell, M.T. Nascimento, R. Colome, J. Genovés, M. Naudó, A. Nascimento. Four sisters compound heterozygotes for the pre-and full mutation in fragile X syndrome and a complete inactivation of X-functional chromosome: implications for genetic counseling, J. Hum. Genet. 56 (1) (2011) 87-90, https://doi.org/ 10.1038/jhg.2010.140 [DOI:10.1038/jhg.2010.140]

12. P.L. Sorensen, K. Basuta, G. Mendoza-Morales, L.W. Gane, A. Schneider, R. Hagerman, et al. A Fragile X Sibship from a Consanguineous Family with a Compound Heterozygous Female and Partially-Methylated Full Mutation Male, Am. J. Med. Genet. Part A.158 (5) (2012) 1221, https://doi.org/ 10.1002/ajmg.a.35293 [DOI:10.1002/ajmg.a.35293]

13. M.G. Linden, F. Tassone, L.W. Gane, J.L. Hills, R.J. Hagerman, A.K. Taylor. Compound heterozygous female with fragile X syndrome, Am. J. Med. Genet. 83 (4) (1999) 318-321. , https://doi.org/10.1002/(SICI)1096-8628(19990402)83:4<318::AID-AJMG16>3.0.CO;2-Y [DOI:10.1002/(SICI)1096-8628(19990402)83:43.0.CO;2-Y]

14. S. Russo, V. Briscioli, F. Cogliati, M. Macchi, F. Lalatta, L. Larizza. An unusual fragile X sibship: female compound heterozygote and male with a partially methylated full mutation, Clin. Genet. 54 (4) (1998) 309-314, https://doi.org/ 10.1034/j.1399-0004.1998.5440408.x [DOI:10.1034/j.1399-0004.1998.5440408.x]

15. M.R. Hegde, M. Fawkner, B. Chong, J. Mcgaughran, D. Gilbert, D.R. Love. Compound heterozygosity at the FMR1 gene, Genet. Test. 5 (2) (2001) 135-138, https://doi.org/ 10.1089/109065701753145600. [DOI:10.1089/109065701753145600.]

16. J. Macpherson, J. Harvey, G. Curtis, T. Webb, D. Heitz, F. Rousseau, et al. A reinvestigation of thirty three fragile (X) families using probe StB12. 3, Am. J. Med. Genet. 43 (5) (1992) 905-912, https://doi.org/ 10.1002/ajmg.1320430535 [DOI:10.1002/ajmg.1320430535]

17. P. Chaste, C. Betancur, M. Gérard-Blanluet, A. Bargiacchi, S. Kuzbari, S. Drunat, et al. High-functioning autism spectrum disorder and fragile X syndrome: report of two affected sisters, Mol. Autism. 3 (1) (2012) 1-6,

18. A.C. Wheeler, D.B. Bailey Jr, E. Berry-Kravis, J. Greenberg, M. Losh, M. Mailick, et al. Associated features in females with an FMR1 premutation, J. Neurodev. Disord. 6 (1) (2014) 1-14,

19. B. Finucane, L. Abrams, A. Cronister, A.D. Archibald, R.L. Bennett, A. Mcconkie-Rosell. Genetic counseling and testing for FMR1 gene mutations: practice guidelines of the national society of genetic counselors, J. Genet. Couns. 21 (6) (2012) 752-760, https://doi.org/ 10.1007/s10897-012-9524-8 [DOI:10.1007/s10897-012-9524-8]

20. M.F. Arlt, S.G. Durkin, R.L. Ragland, T.W. Glover. Common fragile sites as targets for chromosome rearrangements, DNAREP. 5 (9-10) (2006) 1126-1135,